Mark Alan Goldberg, SVP, Medical&Regulatory Affairs at SYNAGEVA BIOPHARMA CORP (GEVA), sold 7,000 shares at $60.49 ($424K) on 2013-12-03, disclosed to the SEC on 2013-12-04.
Scheduled sale ($424k) by SVP, Medical&Regulatory Affairs under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $60.49 | 6,587 | $398K | 94.1% |
| 2 | $61.02 | 413 | $25K | 5.9% |
| Total | $60.52 avg | 7,000 | $424K | 100% |
| Filing → |
| BPMC | SELL | 2020-12-22 | $654K | — | Filing → |
| BPMC | SELL | 2020-12-15 | $627K | — | Filing → |
| BPMC | SELL | 2020-12-03 | $600K | — | Filing → |